PLUS1
1.32
0.04 (3.13%)
0.04 (3.13%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cocrystal Pharma Inc | COCP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.49 | -27.68% | 1.28 | 1.00 | 1.70 | 1.50 | 1.77 | 16:37:41 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1.32 | 1.36 | 0.04 | 2.94% | 1 | 1 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 43,281 | 16,273,596 | $ 1.28 | $ 20,763,130 | 623,028 | 0.3861 - 3.2491 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:37:41 | formt | 600 | $ 1.32 | USD |
Cocrystal Pharma Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 49.46M | 38.64M | $ -49.05M | -1.75 | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Cocrystal Pharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/27/2020 | 11:58 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 2/27/2020 | 07:00 | GlobeNewswire Inc. | Cocrystal Pharma Announces $11.0 Million Registered Direct.. |
| 2/24/2020 | 09:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/24/2020 | 08:00 | GlobeNewswire Inc. | Cocrystal Pharma, Inc. Announces License Agreement with.. |
| 2/18/2020 | 08:31 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/13/2020 | 08:30 | GlobeNewswire Inc. | Cocrystal Pharma Inc.’s Structure-Based Technology has.. |
| 2/11/2020 | 08:35 | GlobeNewswire Inc. | Cocrystal Pharma Inc. to Present at Noble Capital Markets’.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COCP Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.526 | 2.50 | 0.473599 | 1.74 | 33,353,721 | 0.754 | 143.35% |
| 1 Month | 0.549 | 2.50 | 0.473599 | 1.69 | 9,186,378 | 0.731 | 133.15% |
| 3 Months | 0.50 | 2.50 | 0.3861 | 1.61 | 3,291,095 | 0.78 | 156.0% |
| 6 Months | 2.33 | 2.50 | 0.3861 | 1.59 | 1,513,776 | -1.05 | -45.06% |
| 1 Year | 2.70 | 3.2491 | 0.3861 | 1.60 | 763,837 | -1.42 | -52.59% |
| 3 Years | 4.36 | 6.45 | 0.3861 | 1.70 | 420,927 | -3.08 | -70.64% |
| 5 Years | 4.36 | 6.45 | 0.3861 | 1.70 | 420,927 | -3.08 | -70.64% |
Cocrystal Pharma Description
| Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. |
